ResearchWorks Archive
    • Login
    View Item 
    •   ResearchWorks Home
    • Faculty and Researcher Data and Papers
    • Research in Reproduction and Contraception, Center for
    • Center for Research in Reproduction and Contraception
    • View Item
    •   ResearchWorks Home
    • Faculty and Researcher Data and Papers
    • Research in Reproduction and Contraception, Center for
    • Center for Research in Reproduction and Contraception
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Low dose of cyproterone acetate and testosterone enanthate for contraception in men

    Thumbnail
    View/Open
    HumRepro_1998_Low_Dose_Cyproterone.pdf (189.8Kb)
    Date
    1998-05
    Author
    Di Cintio, Giulio
    Costantino, Antonietta
    Flamigni, Carlo
    Meriggiola, M. Cristina
    Bremner, William J.
    Metadata
    Show full item record
    Abstract
    After a control phase, 10 normal men received cyproterone acetate (CPA) at a dose of 25 mg/day (CPA-25; n=5) or 12.5 mg/day (CPA-12.5; n=5) plus testosterone enanthate (TE) 100 mg/week, for 16 weeks. Throughout the study sperm counts were performed every 2 weeks, and luteinizing hormone (LH), follicle stimulating hormone (FSH), testosterone, biochemical and haematological tests were performed every 4 weeks. All five men in group CPA-25 and three men in group CPA-12.5 achieved azoospermia. One man in group CPA-25 was azoospermic by week 12 of hormone administration, but had a sperm count of 0.1 x 10(6)/ml at week 16. Time to azoospermia was 9.0+/-1.3 and 8.7+/-0.7 weeks in groups CPA-25 and CPA-12.5 respectively. Gonadotrophins were decreased by week 4 of hormone administration, remained around the minimum detectability of the assay for the duration of hormone administration and returned to baseline after stopping hormone administration. Testosterone values did not change. No change in any biochemical parameters was found. Haematological parameters were decreased at week 16 of hormone administration and returned to baseline after stopping hormone administration. In conclusion, these results suggest that an hormonal regimen consisting of testosterone plus a progestin with anti-androgenic properties holds promise as an effective, safe and reversible male contraceptive.
    URI
    http://hdl.handle.net/1773/4358
    Collections
    • Center for Research in Reproduction and Contraception [220]

    DSpace software copyright © 2002-2015  DuraSpace
    Contact Us | Send Feedback
    Theme by 
    @mire NV
     

     

    Browse

    All of ResearchWorksCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    DSpace software copyright © 2002-2015  DuraSpace
    Contact Us | Send Feedback
    Theme by 
    @mire NV